NSG mice were irradiated with 200 cGy or not irradiated (0 cGy) and mice from each group were then implanted with 1 mm3 fragments of human fetal thymus and liver in the renal subcapsular space (thymic implant) or left unmanipulated (no thymic implant). All mice were then injected intravenously with 1 × 105 to 5 × 105 CD34+ Tanespimycin haematopoietic stem cells derived from the autologous human CD3-depleted fetal liver. At 12 weeks (a,b,c) and 16 weeks (d,e,f) after implant, the peripheral blood of recipient NSG mice was screened for

human CD45+ cell chimerism (a,d), T cell development (b,e) and B cell development (c,f). Each colour represents a unique set of donor tissues, and each symbol type indicates the specific implant protocol Buparlisib order used to generate the mice. Each point represents an individual mouse. “
“Dendritic cell (DC) modification is a potential strategy to induce clinical transplantation tolerance.

We compared two DC modification strategies to inhibit allogeneic T-cell proliferation. In the first strategy, murine DCs were transduced with a lentiviral vector expressing CTLA4-KDEL, a fusion protein that prevents surface CD80/86 expression by retaining the co-stimulatory molecules within the ER. In the second approach, DCs were transduced to express the tryptophan-catabolising enzyme IDO. CTLA4-KDEL-expressing DCs induced anergy in alloreactive T cells and generated both CD4+CD25+ and CD4+CD25− Treg cells (with direct and

indirect donor allospecificity and capacity for linked suppression) both in vitro and in vivo. In contrast, T-cell unresponsiveness induced by IDO+ DCs lacked donor specificity. In the absence of any immunosuppressive treatment, i.v. administration of CTLA4-KDEL-expressing DCs resulted in long-term survival of corneal allografts Gemcitabine supplier only when the DCs were capable of indirect presentation of alloantigen. This study demonstrates the therapeutic potential of CTLA4-KDEL-expressing DCs in tolerance induction. “
“Lipid mediators derived from essential fatty acids, such as arachidonic acid, play important roles in physiologic and pathophysiologic processes. Prostaglandins, thromboxane, and leukotrienes are well-known eicosanoids that play critical roles in hemodynamics and inflammation. New families of mediators were recently uncovered that constitute a new genus stimulating resolution of acute inflammation, and are organ-protective. These include the resolvins (E-series and D-series), protectins (neuroprotectin D1/protectin D1), and maresins biosynthesized from omega-3 essential fatty acids. Phagocytes play major roles in tissue homeostasis and have a high capacity to produce these mediators, which depend on their tissue and state of activation. It is important to select appropriate methods for identifying target mediators and pathway biomarkers.